Ambria Capital, LLC
Ambria Capital, LLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ambria Capital, LLC.
Ambria Capital, LLC is a company.
Key people at Ambria Capital, LLC.
Ambria Capital, LLC is a venture capital firm founded in 2019 (with roots in 2018 investments) that empowers early-stage companies in mental health and technology sectors, particularly psychedelics, digital health, cryptocurrency, and cybersecurity.[1][2][4] Its mission centers on backing entrepreneurs transforming markets and improving lives amid rising mental health crises, such as spiking suicide rates and untreated conditions, by supporting psychedelic-assisted therapies backed by clinical trials, FDA designations, and growing investment.[2] The firm has made 8 investments, adopts a hands-on approach with its own capital for long-term support, and influences the startup ecosystem through industry expertise, relationships, and advocacy for innovations like psychedelics in healthcare.[1][4]
Ambria Capital emerged from founder and Managing Partner Michael Sobeck's vision in 2018, when he began investing personal capital in early-stage frontier companies in healthcare and technology, formalizing the firm in 2019.[1][4] Sobeck, with over 15 years of experience, leads strategy and is a leading psychedelics investor, co-founding the Perception Restoration Foundation to address disorders like HPPD and Visual Snow Syndrome.[4] Key team member Cody, passionate about psychedelic therapies, has backed over 50 companies, earning 2021 Investor of the Year at the Microdose Awards; the firm has evolved from broad healthcare/tech bets—including agriculture and consumer—to a sharp focus on mental health revolutions via psychedelics and tech like cybersecurity and crypto.[2][3][4]
Ambria Capital rides the psychedelics revolution in mental health—a trillion-dollar opportunity fueled by clinical trial successes outperforming antidepressants, FDA breakthrough statuses, surging capital, and shifting public sentiment amid a crisis affecting tens of millions.[2] Timing is critical as regulatory approvals near, positioning the firm to catalyze a paradigm shift from inadequate traditional care.[2] Market forces like growing overdose epidemics and unmet treatment needs favor its bets, while broader tech intersections (cybersecurity, crypto, digital health) amplify impact.[1][2] It influences the ecosystem by funding visionary founders, fostering awareness via foundations, and bridging private/public companies in agriculture, consumer, healthcare, and tech.[3][4]
Ambria's influence will expand as psychedelics gain approvals and scale, potentially unlocking massive markets in mental healthcare while its tech bets hedge against diversification needs.[2] Trends like AI-enhanced digital health, crypto for secure therapies, and cybersecurity for data-sensitive biotech will shape its path, with the firm's flexible model ideal for volatile frontiers.[1][2] Expect deeper portfolio growth, more advocacy wins, and evolved leadership in impact investing—empowering the next wave of life-changing entrepreneurs from its proven origins.[4]
Key people at Ambria Capital, LLC.
